OREANDA-NEWS. Pharmaceutical plant “Sotex”, which is part of “PROTEK” group of companies, opened a site for production of genetically engineered erythropoietin substance - active ingredient of drug Eralfon® - as a part of the second stage of developing the plant's capacity. The opening was attended by Moscow Region Governor Andrey Vorobiev, Chairman of the Board of Directors of JSC “PROTEK” Vadim Yakunin, and President of JSC “PROTEK” Vadim Muzyaev. Currently, “Sotex” has a complete cycle of production of erythropoietin: from the development and synthesis of substance to the production of innovative form and its release on the market.

Moscow Region Governor Andrey Vorobiev said that the plant “Sotex” - “is a modern, innovative enterprise complying with international standards that allows not only to provide the Russian Federation, and in particular residents of Moscow region, with the most advanced drugs, but also, importantly, supply the drugs for export. We came here to show our interest in supporting such enterprises, and I know that the company has plans to invest additional funds to expand production. We not only support these initiatives, but will do everything to encourage them” said Andrey Vorobiev after visiting the plant.

Opening of a new site for production of erythropoietin is a continuation of the company's commitment to developing science-based biotech drugs. In the future, “Sotex” plans to release new products using advanced production technologies, including genetic engineering. This work is determined by “PROTEK” group of companies as a priority direction of company development within the objectives of the government Strategy of Pharmaceutical Industry Development “Pharma 2020”. The project is financed from own funds of JSC “PROTEK”.

“Sotex” is the only Russian company that produces erythropoietin drugs in a convenient and safe for patients and caregivers form of pre-filled syringes with automatic needle protection. This helps to avoid accidental injury, as the needle is automatically locked immediately after the injection. Thanks to a comfortable pharmaceutical form, Eralfon® considerably simplifies the process of treatment.

Eralfon® is a socially significant drug of genetically engineered erythropoietin group. This drug is used for the prevention and treatment of anemia in oncology, gynecology, rheumatology, neonatology, and in human immunodeficiency virus carriers, as well as for treatment of anemia of various origins. Eralfon® is included in the List of Vital and Essential Medicinal Products.